Hemlibra (Emicizumab)

Hemlibra is indicated for prophylactic treatment of hemophilia A, both with and without factor VIII inhibitors, to reduce the frequency of bleeding episodes.

• Prevention of spontaneous joint and muscle bleeds in patients with hemophilia A.
• Routine prophylaxis in adults and adolescents with factor VIII inhibitors.
• Maintenance therapy for patients without inhibitors to maintain hemostasis.
• Use as part of individualized treatment plans when standard factor VIII replacement is unsuitable.
• Option for patients preferring subcutaneous administration over intravenous factor infusions.

The safety profile of Hemlibra includes a range of observed adverse events, which are categorized by frequency and severity.

Common

• Injection site reactions, including redness, swelling, itching, or mild pain at the subcutaneous site.
• Headache of mild to moderate intensity.
• Symptoms of upper respiratory tract infection, such as sore throat, nasal congestion, or cough.
• Nausea, occasional vomiting, or mild abdominal discomfort.

Serious

• Thrombotic microvascular events, including thrombotic thrombocytopenic purpura or disseminated intravascular coagulation.
• Development of neutralizing anti‑emicizumab antibodies that may diminish therapeutic effect.
• Severe hypersensitivity reactions, including anaphylaxis or angioedema.

When prescribing Hemlibra, clinicians should consider several precautionary measures to ensure safe use.

• Assess patient history for thrombotic disorders before initiating therapy.
• Monitor for signs of thrombosis, especially in patients receiving concomitant pro‑coagulant agents.
• Evaluate for the presence of anti‑drug antibodies during treatment.
• Use caution in individuals with known hypersensitivity to emicizumab or any excipients.
• Consider pregnancy and lactation status; limited data are available on safety.
• Adjust dosing in patients with severe renal or hepatic impairment only under specialist guidance.

Hemlibra may interact with other medicines that affect coagulation or immune response, requiring careful management.

Avoid

• Concurrent use of activated pro‑coagulant agents such as recombinant activated factor VII (rFVIIa) or activated prothrombin complex concentrates, which can increase thrombotic risk.
• Simultaneous administration of other bispecific antibodies targeting coagulation pathways.
• High‑dose bypassing agents such as activated prothrombin complex concentrate (aPCC) exceeding recommended limits.

Use with caution

• Intravenous factor VIII replacement therapy, especially in patients with inhibitors, due to potential additive clotting effects.
• Antifibrinolytic agents (e.g., tranexamic acid) when used for surgery or trauma.
• Immunosuppressive drugs that may alter antibody formation or clearance.
• Vaccinations, particularly live vaccines, should be timed appropriately as they may affect immune response.